Orin Bloch, M.D., FAANS
Skull Base Surgery
- Associate Professor
Philosophy of Care
I strive to provide the best possible treatment for each patient based on their individual needs and desires. Every patient is unique with their own goals, expectations, and fears.
I recognize that surgery is not always the right answer for every patient. I utilize a personalized, multi-disciplinary approach combining surgical procedures, radiation, and drug therapy as appropriate for each patient, based on the highest quality evidence and leading-edge science.
There is no such thing as an untreatable tumor. Not all patients can be cured, but quality of life can always be addressed.
Dr. Bloch specializes in neurosurgical oncology and is an internationally recognized leader in the management of patients with brain cancer. His clinical practice is focused on innovative treatments for benign and malignant tumors of the brain and skull base, including metastatic disease to the brain. His surgical expertise includes awake craniotomies for eloquent tumors, minimally invasive brain surgery, stereotactic laser ablation for tumors, and stereotactic radiosurgery.
In addition to the surgical treatment of brain tumors, Dr. Bloch is a leader in the development of immunotherapy for primary and metastatic tumors of the brain. He directs the UC Davis Brain Tumor Immunotherapy Laboratory funded by support from the NIH/NCI. He has been the principal investigator of multiple national clinical trials of vaccine and checkpoint immunotherapy for glioblastoma. Dr. Bloch has authored more than 100 peer-reviewed publications and book-chapters, and served on the editorial board or as a reviewer for numerous journals. He has been a member of the executive committee of the AANS/CNS Joint Sections on Tumors since 2014.
At UC Davis, Dr. Bloch works closely with a multidisciplinary team of surgeons, scientists, oncologists, and radiation oncologists to provide the most advanced treatments for patients with brain tumors.
Dr. Bloch’s research is focused on innovative new therapies for the treatment of primary and metastatic cancers of the brain. His laboratory studies mechanisms of immune resistance in patients with cancer to identify new targets to enhance the immune response to tumors. Additionally, Dr. Bloch’s Brain Tumor Immunotherapy Laboratory provides immune monitoring and biomarker development for pre-clinical and clinical trials of immunotherapy for glioblastoma, the most common and malignant type of brain tumor. The laboratory has been continuously funded by NIH since 2013 and has produced numerous trainees who are now in practice around the United States advancing the care of brain tumor patients.
Dr. Bloch is also highly involved in clinical research and clinical trials to improve outcomes for his patients. His current studies are focused on the use of vaccine therapies for glioblastoma, viral therapies for glioblastoma, immune checkpoint modulation for glioblastoma and brain metastases, laser ablation therapy combined with immunotherapy, and stereotactic radiosurgery combined with immunotherapy.
M.D., UCSF, 2006
Postdoctoral fellowship in cancer immunology, UCSF, 2012-2013
B.S., University of Pennsylvania, 2001
Neurological Surgery, UCSF, 2006-2012
American Association of Neurological Surgeons
American Association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS) Section on Tumors
Congress of Neurological Surgeons
North American Skull Base Society
Society for Neuro-oncology
Honors and Awards
Ivan Ciric Distinguished Educator Award, Northwestern University, Dept of Neurosurgery, 2018,
Ronald L. Bittner Award, American Association of Neurological Surgeons, 2013,
Rosegay Award, San Francisco Neurological Society, 2012,
Stryker Neuro-Oncology Award, Congress of Neurological Surgeons, 2011,
Alpha Omega Alpha Medical Honor Society, UCSF, 2005,
Select Recent Publications
Bloch O, Han SJ, Cha S, Sun MZ, Aghi MK, McDermott MW, Berger MS, Parsa AT. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg, 2012 Dec;117(6):1032-8. PMID: 23039151.
Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res, 2013 Jun 15;19(12):3165-75. PMID: 23613317; PMCID: PMC3742575.
Bloch O, Safaee M, Sun MZ, Butowski NA, McDermott MW, Berger MS, Aghi MK, Parsa AT. Disseminated progression of glioblastoma after treatment with bevacizumab. Clin Neurol Neurosurg, 2013 Sep;115(9):1795-801. PMID: 23706614.
Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, Butowski NA, Chang SM, Clarke JL, McDermott MW, Prados MD, Sloan AE, Bruce JN, Parsa AT. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol, 2014 Jan;16(2):274-9. PMID: 24335700; PMCID: PMC3895386.
Sun MZ, Oh T, Ivan ME, Clark AJ, Safaee M, Sayegh ET, Kaur G, Parsa AT, Bloch O. Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma. J Neurosurg, 2015 May;122(5):1144-50. PMID: 25768833.
Bloch O. Immunotherapy for malignant gliomas. Cancer Treat Res, 2015;163:143-58. PMID: 25468230.
Lamano JB, Ampie L, Choy W, Kesavabhotla K, DiDomenico JD, Oyon DE, Parsa AT, Bloch O. Immunomonitoring in glioma immunotherapy: current status and future perspectives. J Neurooncol, 2016 Mar:127(1):1-13. PMID:26638171.
Bloch O, Lim M, Sughrue ME, Komotar RJ, Abrahams JM, O’Rourke DM, D’Ambrosio A, Bruce JN, Parsa AT. Autologous heat shock protein peptide vaccination for newly diagnosed glioblastoma: Impact of peripheral PD-L1 expression on response to therapy. Clin Cancer Res, 2017 Jul 15;23(14):3575-84. PMID: 28193626; PMCID: PMC5511566.
DiDomenico JD, Lamano JB, Oyon DE, Li Y, Veliceasa D, Kaur G, Ampie L, Choy W, Lamano JB, Bloch O. The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma. Oncoimmunology. 2018, Apr 25; 7(7):e1448329. PMID: 29900065; PMCID: PMC5993506.
Lamano JB, Lamano JB, Li YD, DiDomenico JD, Choy W, Veliceasa D, Oyon DE, Fakurnejad S, Ampie L, Kesavabhotla K, Kaur R, Kaur G, Biyashev D, Unruh D, Horbinski C, James CD, Parsa AT, Bloch O. Glioblastoma-Derived IL-6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth. Clin Cancer Res. 2019 (In Press).
For a complete list of Dr. Bloch's publications, please click here.